Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in pediatric Crohn's disease
NL-OMON60880Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Started Sep 2024; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON60880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60880.